Neoflow Technologies

Neoflow Technologies Ltd. develops novel endovascular solution for the treatment of vasospasm in Aneurysmal Subarachnoid Hemorrhage (aSAH). Vasospasm is a critical condition leading to Delayed Ischemic Neurological Deficit (DIND) and counts as the major complication of aneurysmal Subarachnoid Hemorrhage (aSAH) in ~40% of all cases. Nowadays, treatment divides into two approaches as follows, the pharmacological approach and the balloon angioplasty treatment. Pharmacological effectiveness is questioned due to the limitations and associated risks. Administration of vasodilators leads to a Blood Pressure drop, which is restricted to a specific group of patients, while Triple H treatment imposes the risk of additional aneurysmal bursting. While the balloon angioplasty treatment effectiveness is strict, associated risks of blood vessel rupture and atherosclerosis plaque fracture embolization keep the treatment out of common practice in some of the leading neurovascular centers around the globe.